Clinical trial
A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With…
NCT00050830 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00050830 |
|---|---|
| Title | A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Neoplasms |
| Intervention type | Drug |
| Interventions | CI 1033 |
| Enrollment | 163 |
| Start date | Jan 1, 2003 |
| Completion | Nov 1, 2005 |
| First posted | Dec 24, 2002 |
| Last update posted | Nov 8, 2006 |
| Countries | Canada, Germany, Ireland, Italy, Netherlands, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: